Nipun Verma

TL;DR: The iCRISPR platform is uniquely suited for dissection of complex genetic interactions and pleiotropic gene functions in human disease studies and has the potential to support high-throughput genetic analysis in hPSCs.

TL;DR: This Protocol Review discusses the unprecedented opportunity that CRISPR/Cas9 technology offers for investigating and manipulating the epigenome to facilitate further understanding of stem cell biology and engineering of stem cells for therapeutic applications.

TL;DR: It is concluded that TET proteins safeguard bivalent promoters from de novo methylation to ensure robust lineage-specific transcription upon differentiation.

TL;DR: This work investigates the association between human GATA6 haploinsufficiency and a wide range of clinical phenotypes that include neonatal and adult-onset diabetes using CRISPR/Cas9-mediated genome editing coupled with human pluripotent stem cell (hPSC) directed differentiation and establishes an approach for identifying genetic modifiers of human disease.

TL;DR: iCRISPR, an efficient gene-editing platform recently developed, is used to demonstrate a knockin strategy without drug selection for both active and silent genes in hESCs, expected to greatly facilitate the use of hESC for developmental studies, disease modeling, and cell-replacement therapy.